
Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 Analysis
The Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 size is worth USD 12.82 Billion in 2025, growing at an 5.76% CAGR and is forecast to hit USD 16.96 Billion by 2030.
The surge in demand for glass packaging to curb product contamination is the primary driver propelling the Asia-Pacific pharmaceutical glass packaging 乐鱼体育官网. This momentum is primarily attributed to the pharmaceutical sector's rapid expansion, fueled by a burgeoning population, increased public healthcare expenditures, and heightened health awareness.
- The Asia-Pacific pharmaceutical sector is expanding, and this growth has led to heightened demand for top-tier packaging solutions. These solutions are crucial for maintaining pharmaceuticals' efficacy and safety, and glass packaging has emerged as the go-to choice in this landscape.
- Glass packaging's inert properties significantly reduce the risk of chemical reactions with the contents, while its superior barrier capabilities shield drugs from oxygen, moisture, and other destabilizing factors. Notably, its eco-friendly and recyclable nature resonates with the prevailing sustainability ethos.
- The demand for glass packaging in developing countries such as India is expected to increase as the country is a prominent and expanding player in the global pharmaceuticals 乐鱼体育官网. According to data published on the India Brand Equity Foundation website, India is one of the world's largest providers of generic pharmaceuticals, accounting for 20% of the global supply and meeting over 60% of global vaccine demand.
- Notably, countries like China, India, and Japan are witnessing a surge in their pharmaceutical industries, increasing the demand for glass packaging solutions. China, renowned as the largest exporter of glasses and glassware, sees widespread applications for its products. Furthermore, as pivotal players in the regional pharmaceutical landscape, China and India are witnessing a notable uptick in drug production and consumption.
- However, glass packaging faces fierce competition from other forms of packaging in the region. The pharma industry is also looking for various alternative materials for commercial reasons. Multiple reasons for pharma companies to switch are loadability, breakages, and unit cost. Glass manufacturers are developing lightweight and durable bottles for pharma to compete with other alternatives.
Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 Trends
China is Expected to have a Significant Share During the Forecast Period
- China's pharmaceutical glass packaging 乐鱼体育官网 is expected to grow as the country has built a standard system for the pharmaceutical industry over the years. The country pays increasing attention to the stability of pharmaceutical packaging materials during the drug storage period and their safety when used.
- The Chinese pharmaceutical sector has grown remarkably, propelling it from a manufacturing hub to a pivotal R&D center. This evolution has firmly established China as a critical global pharmaceutical player, a significant consumer, and a burgeoning R&D epicenter. EqualOcean reports that in 2022, China's pharmaceutical R&D expenditure stood at approximately USD 285 billion. Projections suggest this figure is set to surge, with expectations that by 2023, the nation's total pharmaceutical R&D spending will soar to USD 342 billion.
- The country also witnesses various events and exhibitions to promote glass packaging. In April 2024, China Glass, held at the Shanghai New International Expo Centre, focused on the glass industry's high-end, innovative, and green development. Companies such as Fives Group showcased their full range of solar glass technology and dedicated services at the China Glass exhibition.
- Additionally, Fives Group has forged partnerships with PV glass manufacturers in China for over two decades. It specializes in crafting and delivering cutting-edge rolling machines, catering to local and global 乐鱼体育官网s. The company's prowess lies in deploying patented technologies, guaranteeing peak performance, superior quality, and heightened energy efficiency in green glass manufacturing.

The Ampoules Segment Held a Significant Share in the 乐鱼体育官网
- Due to its alkaline and hydrolytic properties, glass is a widely used packaging material for pharmaceutical and personal care products. It provides high transparency, allowing for easy inspection of contents, increased protection due to its relatively impermeable properties to air and moisture, and chemical resistance to most medicinal products.
- Companies operating in the region are focused on expanding their business by innovating new products and expanding capacity. In March 2023, players such as Schott began manufacturing amber pharmaceutical glass domestically in India to meet the increasing demand for pharmaceutical packaging, including ampoules, syringes, vials, and other drugs in Asia.
- Ampoules are an essential component of parenteral pharmaceutical packaging. The increasing geriatric population, the prevalence of chronic conditions, and the preference for injectable treatments have led to a surge in demand for ampoules. Furthermore, players in the ampoule glass packaging 乐鱼体育官网 are introducing high-speed fill lines to enhance the functionalities of glasses with high dimensional stability, thus augmenting their manufacturing capabilities.
- The need for vaccine storage for diseases like hepatitis B, tuberculosis, chickenpox, and polio drives the 乐鱼体育官网's growth. Additionally, Pharmaceutical sales in Asian countries have grown in recent years. According to CPhI South East Asia, pharmaceutical sales in South Asia, where Indonesia is projected to reach USD 16.05 billion in 2024, followed by Vietnam with USD 9.84 billion, are expected to fuel glass packaging in the pharmaceutical 乐鱼体育官网 during the forecast period.
- The rise of chronic ailments, such as cancer and diabetes, has highlighted the necessity for advanced drug delivery technologies. Healthcare professionals are increasingly advocating for injectables, particularly in specific scenarios. Furthermore, the utilization of premium injectables has bolstered patient confidence. Consequently, the expansion of the injectable drug delivery 乐鱼体育官网 hinges significantly on the widespread adoption of these invasive techniques. The advocacy and expertise of trained medical personnel have further amplified the demand for ampoules.

Asia Pacific Pharmaceutical Glass Packaging Industry Overview
The Asia-Pacific glass packaging 乐鱼体育官网 is fragmented, with increasing investments and the launch of injectables and other medicines opening opportunities in the sector. Rivalry among competitors such as Becton, Dickinson and Company, SGD SA, Gerresheimer AG, Schott AG, and AGI glaspac -AGI Greenpac Limited is high. Horizontal and vertical integration of companies in the pharmaceutical industry is anticipated to fuel the demand for glass packaging.
- June 2024 - BD (Becton, Dickinson, and Company), a global medical technology company, and Edwards Lifesciences announced an agreement under which BD will acquire Edwards' Critical Care product group, one of the global leaders in advanced monitoring solutions, for聽USD 4.2 billion. This will unlock new value-creation opportunities and enhance BD's innovative connected care solutions portfolio.
- October 2023 - SCHOTT AG is constantly enhancing its materials while making them more sustainable. With its borosilicate glass being the gold standard for storing lifesaving medications for over a century, the company is taking the following steps by introducing improved glass tubing to the global pharmaceutical 乐鱼体育官网. FIOLAX Pro is a new type I borosilicate glass developed to address three significant trends in increasingly complex pharmaceuticals: sustainable products, circular economy, and digitalization.
Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 Leaders
-
AGI glaspac - AGI Greenpac Limited
-
Schott AG
-
Becton, Dickinson, And Company
-
Gerresheimer AG
-
SGD S.A.
- *Disclaimer: Major Players sorted in no particular order

Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 News
- June 2024: Chugai Pharmaceutical Co. Ltd聽announced that Maruho Co. Ltd (hereafter, Maruho) launch of Mitchga Subcutaneous Injection 30mg Vials (Japanese Accepted Name (JAN): nemolizumab (Genetical Recombination)) in Japan for the treatment of the following conditions only when existing treatment is insufficiently effective: pruritus associated with Atopic dermatitis (children aged 鈮�6 and <13 years) and Prurigo nodularis (adults and children aged 鈮�13 years). Mitchga originated from Chugai and has been licensed out to Maruho in Japan.
- March 2024: Aurobindo Pharma commissioned four state-of-the-art manufacturing facilities for penicillin-G, 6-amino Penicillanic Acid (6-APA), Injectable products, and Granulation through its wholly owned subsidiaries. The penicillin-G (Pen-G) facility in an SEZ at Kakinada in Andhra Pradesh, India, has a production capacity of 15,000 tonnes per annum and 180,000 tonnes of glucose. In comparison, the 6-Amino Penicillanic Acid plant can produce 3,600 tonnes yearly.
Asia Pacific Pharmaceutical Glass Packaging Industry Segmentation
Glass has long been the preferred material for producing secure packaging in the pharmaceutical industry. Its chemical stability and immobility properties make it an ideal material for packaging medicinal products, including solids, liquids, injectables, and reconstituted products.
The Asia-Pacific pharmaceutical glass packaging 乐鱼体育官网 is segmented by products (bottles, vials, ampoules, cartridges, syringes, and other products) and country (China, Japan, India, Australia and New Zealand, and Rest of Asia-Pacific). The 乐鱼体育官网 sizes and forecasts are provided in value (USD) for all the above segments.
By Products | Bottles |
Vials | |
Ampoules | |
Cartridges and Syringes | |
Other Products | |
By Country*** | China |
Japan | |
India | |
Australia and New Zealand |
Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 Research FAQs
How big is the Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网?
The Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 size is worth USD 12.82 billion in 2025, growing at an 5.76% CAGR and is forecast to hit USD 16.96 billion by 2030.
What is the current Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 size?
In 2025, the Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 size is expected to reach USD 12.82 billion.
Who are the key players in Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网?
AGI glaspac - AGI Greenpac Limited, Schott AG, Becton, Dickinson, And Company, Gerresheimer AG and SGD S.A. are the major companies operating in the Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网.
What years does this Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 cover, and what was the 乐鱼体育官网 size in 2024?
In 2024, the Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 size was estimated at USD 12.08 billion. The report covers the Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Asia Pacific Pharmaceutical Glass Packaging Industry Report
Statistics for the 2025 Asia Pacific Pharmaceutical Glass Packaging 乐鱼体育官网 share, size and revenue growth rate, created by Mordor Intelligence鈩� Industry Reports. Asia Pacific Pharmaceutical Glass Packaging analysis includes a 乐鱼体育官网 forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.